Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
01/04/2022 - 08:00 AM
Longeveron CEO Geoff Green to give presentation and will participate in panel discussion titled “The Emerging Cell & Gene Therapy Landscape—From Hope to Reality” moderated by Dr. Scott Gottlieb, former Commissioner of the FDA
MIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer of Longeveron, will present at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participate in a panel discussion moderated by Dr. Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration (FDA). Details of Longeveron’s participation follow below:
Format: Company presentationDate: Available for on-demand viewing starting on Monday, January 10, 2022Time: 7:00 a.m. ET Format: Panel discussion: “The Emerging Cell & Gene Therapy Landscape—From Hope to Reality”Date: Tuesday, January 11, 2022Time: 12:00 p.m. – 1:15 p.m. ET The pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022.
A link to the presentation will be available at the same time via the Investors & Media section of the Company website (www.longeveron.com ). The panel discussion will be available to registered conference attendees.
About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Contact: Brendan Payne Stern Investor Relations Tel: (212) 362-1200 Email: Brendan.payne@sternir.com
Source: Longeveron Inc.
LGVN Rankings
#4629 Ranked by Stock Gains
LGVN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About LGVN
longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome